Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Stemcell United Ltd. ( (AU:BP8) ) has shared an update.
BPH Global has appointed Ms Ifat Mazouz as full-time Chief Scientific Officer, elevating her from the advisory board to lead all research and development programs with a strong commercial mandate. With nearly two decades of international experience in aquaculture and marine biotechnology, she is tasked with aligning in-house and outsourced R&D with market-focused objectives and investor engagement.
Her immediate priorities include advancing key projects such as finalising the company’s powdered kefir drink product and identifying new revenue-generating opportunities from the R&D pipeline. The role, intended to be based in Melbourne subject to visa approval, is seen by management as a key step in strengthening BPH Global’s push to become a leading player in seaweed innovation and accelerate the transition of its technologies into commercial products.
More about Stemcell United Ltd.
BPH Global Ltd is an ASX-listed company focused on seaweed innovation and marine biotechnology, developing products that leverage aquaculture systems and related research. The company aims to convert its research and development portfolio into scalable, market-ready consumer and industrial products with clear pathways to commercialisation.
Current Market Cap: A$4.71M
For detailed information about BP8 stock, go to TipRanks’ Stock Analysis page.